Digital Therapeutic Development of Virtual Cognitive-Affective Training for Opioid Use Disorder
阿片类药物使用障碍虚拟认知情感训练的数字治疗开发
基本信息
- 批准号:10255561
- 负责人:
- 金额:$ 31.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-05-15 至 2022-08-14
- 项目状态:已结题
- 来源:
- 关键词:AbstinenceAdherenceAffectAffectiveAmericanArea Under CurveBackBehavior TherapyBehavioralBiochemicalBiometryBrainBuprenorphineCOVID-19 pandemicClinicClinicalClinical ResearchCloud ComputingCognitiveComputerized Medical RecordCustomDataDevelopmentDropoutEcological momentary assessmentEducational InterventionElectronic Health RecordEnvironmentEpidemicFast Healthcare Interoperability ResourcesFeedbackFundingGoalsHealth Services AccessibilityHumanHuman ResourcesIndividualIngestionInterventionLightLinkMachine LearningMeasurementMeasuresMedical DeviceNational Institute of Drug AbuseOpioidOutcomeParticipantPatientsPharmaceutical PreparationsPhasePlant RootsProcessProtocols documentationPsychophysiologyRandomized Controlled TrialsRecordsRecoveryRegulatory PathwayRelapseResearch DesignResourcesRewardsRiskSafetySelf EfficacyServicesSignal TransductionSmall Business Innovation Research GrantSpecific qualifier valueSumSystemTechniquesTeleconferencesTestingTherapeutic EffectTrainingTranslatingTreatment outcomeUnited StatesUnited States Food and Drug AdministrationViraladdictionaffective neurosciencearmbarrier to carebiobehaviorchronic painclinical efficacycommercializationcravingcue reactivitydesigndigital treatmenteffective interventionefficacy studyelectronic dataevidence baseexperienceimplementation barriersimprovedinnovationmeetingsmindfulnessneurophysiologynovelopioid epidemicopioid misuseopioid treatment programopioid useopioid use disorderpatient engagementpatient safetyphase 1 studyprescription opioidpreventprogramspromoterprototyperesponsereward processingsatisfactionskillssuccesstherapeutic developmenttherapy developmenttreatment as usualtreatment programtreatment risktreatment strategyusabilityvirtualvirtual machinevirtual realityvirtual reality system
项目摘要
Project Summary: The US is experiencing an opioid crisis, with an estimated 2.5 million Americans meeting
full criteria for opioid use disorder (OUD). Medications for opioid use disorder (MOUD) like buprenorphine are
currently the most effective form of intervention for OUD. In spite of the proven efficacy of MOUD, nearly half of
people who begin a MOUD relapse within six months. As such, novel and efficacious behavioral adjuncts to
MOUD are needed to improve treatment outcomes. Mindfulness-Oriented Recovery Enhancement (MORE), a
cognitive-affective training intervention generated through a NIDA-funded treatment development process has
shown significant promise, demonstrating therapeutic effects in four randomized controlled trials (RCTs) by
reducing opioid use and misuse and modulating neurophysiological responses during drug cue-reactivity and
natural reward processing. However, the MORE intervention requires significant human interaction and is
therefore resource intensive. Further, in light of the COVID-19 pandemic, people with OUD may be reticent to
engage in face-to-face interventions due to the risk of viral spread. To overcome these implementation barriers
and increase access to treatment, the proposed project will develop and test a virtual reality version of the
MORE intervention (MORE-VR) built on BehaVR LLC's VR existing, commercially available platform, the
Dynamic eXperience Engine (DXE). The DXE uses machine learning to integrate biometrics into the VR
experience to personalize addictions treatment, boosting patient engagement and optimizing the efficacy of
clinical intervention. In Phase I, we will develop and test the MORE-VR prototype in a single arm clinical study
of OUD patients receiving buprenorphine in an opioid treatment program (OTP), focusing on patient safety and
engagement. If the prototype is perceived to have adequate usability and Net Promoter Scores, as well as to
produce improvements in proximal measures of craving and affective state, the project will progress to Phase
II. In Phase II, we will first develop the MORE-VR Minimal Viable Program using feedback from our Phase I
study to optimize the intervention, and then conduct a RCT of MORE-VR vs. MOUD treatment as usual. Our
robust and unbiased research design will triangulate clinical outcome measurement with biochemical
verification of abstinence, ecological momentary assessments (EMA), and neurophysiological assessment of
cue-reactivity. Further, we will integrate the MORE-VR Program into the OTP operational environment, building
Fast Healthcare Interoperability Resources interfaces to ingest patient data from electronic medical records
(EMRs) and to export patient utilization, assessment, and biometric data back to EMRs to create patient
records and inform clinicians of patient progress. Activities in Phase I and Phase II will help define the
regulatory pathway and establish regulatory feasibility to precede Food and Drug Administration (FDA)
approval of the MORE-VR system as a Class II medical device. In sum, this project will translate an evidence-
based biobehavioral treatment approach into an innovative digital therapeutic for OUD.
美国正在经历阿片类药物危机,估计有250万美国人
阿片类药物使用障碍(OUD)阿片类药物使用障碍(MOUD),如丁丙诺啡,
目前,这是对OUD最有效的干预形式。尽管MOUD的有效性已得到证实,但近一半的
在六个月内开始复发的人。因此,新颖有效的行为抑制剂,
需要MOUD来改善治疗结果。正念导向的恢复增强(更多),a
通过NIDA资助的治疗开发过程产生的认知情感训练干预,
显示出显著的前景,在四项随机对照试验(RCT)中证明了治疗效果,
减少阿片类药物的使用和滥用,调节药物线索反应期间的神经生理反应,
自然奖励处理然而,MORE干预需要大量的人际互动,
因此资源密集。此外,鉴于COVID-19大流行,OUD患者可能对
由于病毒传播的风险,参与面对面的干预。为了克服这些实施障碍,
并增加获得治疗的机会,拟议的项目将开发和测试一个虚拟现实版本的
MORE干预(MORE-VR)建立在BehaVR LLC的VR现有商用平台上,
动态体验引擎(DXE)。DXE使用机器学习将生物识别技术集成到VR中
个性化成瘾治疗的经验,提高患者参与度并优化
临床干预。在第一阶段,我们将在单臂临床研究中开发和测试MORE-VR原型
OUD患者在阿片类药物治疗计划(OTP)中接受丁丙诺啡,重点关注患者安全性,
订婚如果原型被认为具有足够的可用性和净推荐值,以及
在渴望和情感状态的近端测量中产生改善,项目将进展到阶段
二.在第二阶段,我们将首先根据第一阶段的反馈开发MORE-VR最小可行计划
研究以优化干预,然后照常进行MORE-VR与MOUD治疗的RCT。我们
稳健和无偏见的研究设计将临床结果测量与生化指标进行三角测量。
禁欲验证,生态瞬时评估(EMA)和神经生理学评估,
线索反应性此外,我们还将MORE-VR计划整合到OTP操作环境中,
快速医疗保健互操作性资源接口可从电子病历中获取患者数据
(EMR),并将患者使用、评估和生物特征数据导出回EMR,以创建患者
记录并告知临床医生患者的进展情况。第一阶段和第二阶段的活动将有助于确定
监管途径,并建立监管可行性,以先于美国食品药品监督管理局(FDA)
批准MORE-VR系统为II类医疗器械。总之,这个项目将翻译一个证据-
基于生物行为的治疗方法转化为OUD的创新数字治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RISA B WEISBERG其他文献
RISA B WEISBERG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RISA B WEISBERG', 18)}}的其他基金
Digital Therapeutic Development of Virtual Cognitive-Affective Training for Opioid Use Disorder
阿片类药物使用障碍虚拟认知情感训练的数字治疗开发
- 批准号:
10676262 - 财政年份:2021
- 资助金额:
$ 31.9万 - 项目类别:
Digital Therapeutic Development of Virtual Cognitive-Affective Training for Opioid Use Disorder
阿片类药物使用障碍虚拟认知情感训练的数字治疗开发
- 批准号:
10624991 - 财政年份:2021
- 资助金额:
$ 31.9万 - 项目类别:
Cognitive-behavioral Treatment of Anxiety/ Primary Care
焦虑的认知行为治疗/初级保健
- 批准号:
7090602 - 财政年份:2004
- 资助金额:
$ 31.9万 - 项目类别:
Cognitive-behavioral Treatment of Anxiety/ Primary Care
焦虑的认知行为治疗/初级保健
- 批准号:
6926064 - 财政年份:2004
- 资助金额:
$ 31.9万 - 项目类别:
Cognitive-behavioral Treatment of Anxiety/ Primary Care
焦虑的认知行为治疗/初级保健
- 批准号:
7447384 - 财政年份:2004
- 资助金额:
$ 31.9万 - 项目类别:
Cognitive-behavioral Treatment of Anxiety/ Primary Care
焦虑的认知行为治疗/初级保健
- 批准号:
7265164 - 财政年份:2004
- 资助金额:
$ 31.9万 - 项目类别:
Cognitive-behavioral Treatment of Anxiety/ Primary Care
焦虑的认知行为治疗/初级保健
- 批准号:
6820173 - 财政年份:2004
- 资助金额:
$ 31.9万 - 项目类别:
相似海外基金
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 31.9万 - 项目类别:
Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 31.9万 - 项目类别:
Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 31.9万 - 项目类别:
Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 31.9万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 31.9万 - 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 31.9万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 31.9万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 31.9万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 31.9万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 31.9万 - 项目类别:
Fellowship Programs